# Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

> **NCT00784823** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hackensack Meridian Health** · enrollment: 32 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib 1 mg/m2
- **DRUG:** Bortezomib 1.3 mg/m2
- **DRUG:** Bortezomib 1.6 mg/m2
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT00784823
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00784823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00784823, "Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00784823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*